SOME PECULIARITIES OF SECOND DYSLIPIDEMIA IN PATIENTS WITH TYPE 2 DIABETES
DOI:
https://doi.org/10.11603/1811-2471.2018.v0.i2.8637Keywords:
type 2 diabetes, atherogenic dyslipidemia, arterial hypertension, ischemic heart disease.Abstract
The article describes and analyzes the atherogenicity indicators of the blood lipid profile in patients with type 2 diabetes mellitus (DM), depending on the presence or absence of cardiovascular complications.
The aim of the study – to clarify the atherogenicity of the lipid profile of blood in patients with type 2 diabetes with arterial hypertension (AH), coronary artery disease (CAD), comorbidity of these diseases and without cardiovascular complications.
Material and Methods. The study included 265 patients with type 2 diabetes, divided into groups depending on the presence or absence of cardiovascular pathology. The analysis of the lipid profile of the blood serum was performed on the following parameters: total cholesterol (TCh), triglycerides (TG), high density lipoprotein cholesterol (HDLC), low density lipoprotein cholesterol (LDL), and lipid ratios of TG/LDL, LDLC/HDL, TG/HDLC, with non-esterified fatty acids (NEFA).
Results. All examined groups of patients with type 2 diabetes had changes in lipidograms typical for the atherogenic lipid metabolism profile. These changes included hypertriglyceridemia, elevated LDL levels, and decreased anti-atherogenic HDL. At the same time, the most significant lipidogram changes were noted in type 2 diabetic patients with AH and CAD.
A characteristic feature of CAD and comorbidity of AH and CAD in patients with type 2 diabetes, as compared to a group of type 2 diabetic patients without cardiovascular disease, is statistically significant increase of NEFA level in blood.
The results of the analysis of the integral indicators of atherogenic and antiatherogenic lipid fractions have demonstrated that type 2 diabetic patients with cardiovascular complications, had significantly increased TG/HDL and LDL/HDL ratios. Accordingly, these indicators have a prognostic value in the development of atherosclerotic vascular lesions.
References
Sokolov, E.I., & Perova, N.V. (2003). Diabeticheskaya dislipidemiya v patogeneze ishemicheskoy bolezni serdtsa [Diabetic dyslipidemia in the pathogenesis of coronary heart disease]. Kardiologiya – Cardiology, 43 (5), 16-20 [in Russian].
Afanasyev, D. (2012). Vse okazalas yeshche glubzhe i seryezney – svyazi sakharnogo diabeta i serdechno-sosudistykh zabolevaniy v inkretinovoy sisteme [Everything was even deeper and more serious – the connection of diabetes mellitus and cardiovascular diseases in the incretin system]. Novaya meditsina tysyacheletiya – New Millennium Medicine, 4, 29-35 [in Russian].
Netyazhenko, V., Barna, O., Solomenchuk, T. (2003). Ateroskleroz pry tsukrovomu diabeti ІІ typu: stratehiia likuvannia dyslipidemii [Atherosclerosis in diabetes mellitus type ІІ: strategy of treatment of dyslipidemia]. Liky Ukrainy – Drugs of Ukraine, 10, 4-10 [in Ukrainian].
Chernyshov, V.A., Chyrva, O.V., & Valentynova, I.A. (2016). Deiaki osoblyvosti vtorynnoi dyslipidemii u patsiientiv z vysokym kardiometabolichnym ryzykom [Some features of secondary dyslipidaemia in patients with high cardiomaterial risk]. Ukrainskyi terapevtychnyi zhurnal – Ukrainian Therapeutic Journal, 1, 50-60 [in Ukrainian].
Manjunath, C.N., Rawal, Jayesh R., Irani, Paurus Mehelli (2013). Atherogenic dyslipidemia. Indian. J. Endocrinol. Metab., 17 (6), 969-976.
